Prebiotics and Probiotics in Digestive Health

Clinical Gastroenterology and Hepatology

Volumn 17, Issue 2, 2019, Pages 333-344

  Quigley, Eamonn M M ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Microbiota; Prebiotic; Probiotic; Synbiotics

Indexed keywords

PREBIOTIC AGENT; PROBIOTIC AGENT; SHORT CHAIN FATTY ACID;

BACTERIAL GROWTH; BACTERIAL METABOLISM; BACTERIAL STRAIN; BIFIDOBACTERIUM; BILE ACID METABOLISM; CENTRAL NERVOUS SYSTEM; DIGESTIVE SYSTEM; ECONOMIC ASPECT; FAECALIBACTERIUM PRAUSNITZII; GASTROINTESTINAL DISEASE; HUMAN; IMMUNE RESPONSE; INTESTINE FLORA; LACTOBACILLUS; NEUROENDOCRINE SYSTEM; NONHUMAN; QUALITY CONTROL; REVIEW; DYSBIOSIS; GASTROINTESTINAL TRACT; MICROBIOLOGY; PHYSIOLOGY;

DYSBIOSIS; GASTROINTESTINAL DISEASES; GASTROINTESTINAL MICROBIOME; GASTROINTESTINAL TRACT; HOST MICROBIAL INTERACTIONS; HUMANS; PREBIOTICS; PROBIOTICS;

EID: 85059202122     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2018.09.028     Document Type: Review

References (136)

1. Barbara, G., Feinle-Bisset, C., Ghoshal, U.C., et al. The intestinal microenvironment and functional gastrointestinal disorders. Gastroenterology, 2016 Feb 18 [E-pub ahead of print].
2. Thaiss, C.A., Zmora, N., Levy, M., Elinav, E., The microbiome and innate immunity. Nature 535 (2016), 65–74.
3. Kabouridis, P.S., Pachnis, V., Emerging roles of gut microbiota and the immune system in the development of the enteric nervous system. J Clin Invest 125 (2015), 956–964.
4. O’ Mahony, S.M., Dinan, T.G., Cryan, J.F., The gut microbiota as a key regulator of visceral pain. Pain 158:Suppl 1 (2017), S19–S28.
5. Farzi, A., Fröhlich, E.E., Holzer, P., Gut microbiota and the neuroendocrine system. Neurotherapeutics 15 (2018), 5–22.
6. Dinan, T.G., Cryan, J.F., The microbiome-gut-brain axis in health and disease. Gastroenterol Clin North Am 46 (2017), 77–89.
7. Claesson, M.J., Clooney, A.G., O'Toole, P.W., A clinician's guide to microbiome analysis. Nat Rev Gastroenterol Hepatol 14 (2017), 585–595.
8. O'Toole, P.W., Jeffery, I.B., Microbiome-health interactions in older people. Cell Mol Life Sci 75 (2018), 119–128.
9. Di Pilato, V., Freschi, G., Ringressi, M.N., Pallecchi, L., Rossolini, G.M., Bechi, P., The esophageal microbiota in health and disease. Ann N Y Acad Sci 1381 (2016), 21–33.
10. Hunt, R.H., Yaghoobi, M., The esophageal and gastric microbiome in health and disease. Gastroenterol Clin North Am 46 (2017), 121–141.
11. Ringel, Y., The gut microbiome in irritable bowel syndrome and other functional bowel disorders. Gastroenterol Clin North Am 46 (2017), 91–101.
12. Flemer, B., Warren, R.D., Barrett, M.P., et al. The oral microbiota in colorectal cancer is distinctive and predictive. Gut 67 (2018), 1454–1463.
13. Quigley, E.M.M., Microbiota-brain-gut axis and neurodegenerative diseases. Curr Neurol Neurosci Rep, 17, 2017, 94.
14. Quigley, E.M.M., Gut microbiome as a clinical tool in gastrointestinal disease management: are we there yet?. Nat Rev Gastroenterol Hepatol 14 (2017), 315–320.
15. Kayshap, P.C., Quigley, E.M., Therapeutic implications of the gastrointestinal microbiome. Curr Opin Pharmacol 38 (2018), 90–96.
16. Martini, E., Krug, S.M., Siegmund, B., Neurath, M.F., Becker, C., Mend your fences: the epithelial barrier and its relationship with mucosal immunity in inflammatory bowel disease. Cell Mol Gastroenterol Hepatol 4 (2017), 33–46.
17. Cukrowska, B., Sowińska, A., Bierła, J.B., Czarnowska, E., Rybak, A., Grzybowska-Chlebowczyk, U., Intestinal epithelium, intraepithelial lymphocytes and the gut microbiota - key players in the pathogenesis of celiac disease. World J Gastroenterol 23 (2017), 7505–7518.
18. Guarino, M.P., Cicala, M., Putignani, L., Severi, C., Gastrointestinal neuromuscular apparatus: An underestimated target of gut microbiota. World J Gastroenterol 22 (2016), 9871–9879.
19. Rolig, A.S., Mittge, E.K., Ganz, J., et al. The enteric nervous system promotes intestinal health by constraining microbiota composition. PLoS Biol, 15, 2017, e2000689.
20. Parthasarathy, G., Chen, J., Chen, X., et al. Relationship between microbiota of the colonic mucosa vs feces and symptoms, colonic transit, and methane production in female patients with chronic constipation. Gastroenterology 150 (2016), 367–379.
21. Quigley, E.M., Abu-Shanab, A., Murphy, E.F., Stanton, C., Monsour, H.P. Jr., The Metabolic role of the microbiome: implications for NAFLD and the metabolic syndrome. Semin Liver Dis 36 (2016), 312–316.
22. Taneja, V., Arthritis susceptibility and the gut microbiome. FEBS Lett 588 (2014), 4244–4249.
23. Gibson, G.R., Roberfroid, M.B., Dietary modulation of the human colonic microbiota. Introducing the concept of prebiotics. J Nutr 125 (1995), 1401–1412.
24. Gibson, G.R., Hutkins, R., Sanders, M.E., et al. The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol 14 (2017), 491–502.
25. Codex Alimentarius Committee. Guidelines on nutrition labelling CAC/GL 2-1985 as last amended 2010. Joint FAO/WHO Food Standards Programme, Secretariat of the Codex Alimentarius Commission, 2010, FAO, Rome, Italy.
26. Holscher, H.D., Dietary fiber and prebiotics and gastrointestinal microbiota. Gut Microbes 8 (2017), 172–184.
27. Bindels, L.B., Delzenne, N.M., Cani, P.D., Walter, J., Towards a more comprehensive concept for prebiotics. Nat Rev Gastroenterol Hepatol 12 (2015), 303–310.
28. Vandeputte, D., Falony, G., Vieira-Ailva, S., et al. Prebiotic inulin-type fructans induce specific changes in the human gut microbiota. Gut 66 (2017), 1968–1974.
29. Lilly, D.M., Stillwell, R.H., Probiotics. Growth promoting factors produced by micro-organisms. Science 147 (1965), 747–748.
30. Schrezenmeir, J., de Vrese, M., Probiotics, prebiotics, and synbiotics—approaching a definition. Am J Clin Nutr 73:Suppl (2001), 361S–364S.
31. Food and Agriculture Organization of the United Nations and World Health Organization. Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. World Health Organization. 2001. Available at: http://www.who.int/foodsafety/publications/fs_management/en/probiotics.pdf. Accessed October 29, 2018.
32. Hill, C., Guarner, F., Reid, G., et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 11 (2014), 506–514.
33. Food Safety Authority of Ireland. Probiotic health claims. Available at: http://www.fsai.ie/faq/probiotic_health_claims.html Accessed October 29, 2018.
34. Salminen, S., van Loveren, H., Probiotics and prebiotics: health claim substantiation. Microb Ecol Health Dis 23 (2012), 40–42.
35. van Loveren, H., Sanz, Y., Salminen, S., Health claims in Europe: probiotics and prebiotics as case examples. Annu Rev Food Sci Technol 3 (2012), 247–261.
36. Venugopalan, V., Shriner, K.A., Wong-Beringer, A., Regulatory oversight and safety of probiotic use. Emerging Inf Dis 16 (2010), 1661–1665.
37. Arora, M., Baldi, A., Regulatory categories of probiotics across the globe: a review representing existing and recommended categorization. Indian J Med Microbiol 33:Suppl (2015), 2–10.
38. Rachmilewitz, D., Kayatura, Karmeli, F., et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 126 (2004), 520–528.
39. Jijon, H., Backer, J., Diaz, H., et al. DNA from probiotic bacteria modulates murine and human epithelial and immune function. Gastroenterology 126 (2004), 1358–1373.
40. Kamiya, T., Wang, L., Forsythe, P., et al. Inhibitory effects of Lactobacillus reuteri on visceral pain induced by colorectal distension in Sprague-Dawley rats. Gut 55 (2006), 191–196.
41. Gibson, G.R., Brummer, R.J., Isolauri, E., et al. The design of probiotic studies to substantiate health claims. Gut Microbes 2 (2011), 299–305.
42. Binnendijk, K.H., Rijkers, G.T., What is a health benefit? An evaluation of EFSA opinions on health benefits with reference to probiotics. Benef Microbes 4 (2013), 223–230.
43. Joint Food and Agriculture Organization of the United Nations/World Health Organization Working Group. Report on drafting guidelines for the evaluation of probiotics in food. 2002. Available at: https://www.who.int/foodsafety/fs_management/en/probiotic_guidelines.pdf. Accessed October 29, 2018.
44. Lewis, Z.T., Shani, G., Masarweh, C.F., et al. Validating bifidobacterial species and subspecies identity in commercial probiotic products. Pediatr Res 79 (2016), 445–452.
45. Quigley, E.M.M., Bifidobacteria as probiotic organisms. An introduction. Floch, M.H., Ringel, Y., Walker, M.A., (eds.) The Microbiota in Gastrointestinal Pathophysiology, 2017, Elsevier Academic Press, London, 125–126.
46. Shanahan, F., Quigley, E.M., Manipulation of the microbiota for treatment of IBS and IBD-challenges and controversies. Gastroenterology 146 (2014), 1554–1563.
47. Victor, D.W. 3rd, Quigley, E.M., Microbial therapy in liver disease: probiotics probe the microbiome-gut-liver-brain axis. Gastroenterology 147 (2014), 1216–1218.
48. Quigley, E.M., Probiotics in irritable bowel syndrome: the science and the evidence. J Clin Gastroenterol 49:Suppl 1 (2015), S60–S64.
49. Abraham, B.P., Quigley, E.M.M., Probiotics in inflammatory bowel disease. Gastroenterol Clin North Am 46 (2017), 769–782.
50. Giron, F., Quigley, E.M.M., Pharmabiotic manipulation of the microbiota in gastrointestinal disorders: a clinical perspective. J Neurogastroenterol Motil 24 (2018), 355–366.
51. Dunne, C., Murphy, L., Flynn, S., et al. Probiotics: from myth to reality. Demonstration of functionality in animal models of disease and in human clinical trials. Antonie Van Leeuwenhoek 76 (1999), 279–292.
52. Dunne, C., O'Mahony, L., Murphy, L., et al. In vitro selection criteria for probiotic bacteria of human origin: correlation with in vivo findings. Am J Clin Nutr 73 (2001), 386s–392s.
53. Altmann, F., Kosma, P., O'Callaghan, A., et al. Genome analysis and Characterisation of the exopolysaccharide produced by Bifidobacterium longum subsp. longum 35624. PLoS One, 11, 2016, e0162983.
54. Schiavi, E., Gleinser, M., Molloy, E., et al. The surface-associated exopolysaccharide of Bifidobacterium longum 35624 plays an essential role in dampening host proinflammatory responses and repressing local TH17 responses. Appl Environ Microbiol 82 (2016), 7185–7196.
55. Didari, T., Solki, S., Mozaffari, S., Nikfar, S., Abdollahi, M., A systematic review of the safety of probiotics. Expert Opin Drug Saf 13 (2014), 227–239.
56. Doron, S., Snydman, D.R., Risk and safety of probiotics. Clin Infect Dis 60:Suppl 2 (2015), S129–S134.
57. AlFaleh, K., Anabrees, J., Efficacy and safety of probiotics in preterm infants. J Neonatal Perinatal Med 6 (2013), 1–9.
58. Redman, M.G., Ward, E.J., Phillips, R.S., The efficacy and safety of probiotics in people with cancer: a systematic review. Ann Oncol 25 (2014), 1919–1929.
59. Urben, L.M., Wiedmar, J., Boettcher, E., Cavallazzi, R., Martindale, R.G., McClave, S.A., Bugs or drugs: are probiotics safe for use in the critically ill?. Curr Gastroenterol Rep, 16, 2014, 388.
60. Wang, Y.-H., Yao, N., Wei, K.K., et al. The efficacy and safety of probiotics for prevention of chemoradiotherapy-induced diarrhea in people with abdominal and pelvic cancer: a systematic review and meta-analysis. Eur J Clin Nutr, 70, 2016 1246–1212.
61. Besselink, M.G., van Santvoort, H.C., Buskens, E., et al. Dutch Acute Pancreatitis Study Group. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 371 (2008), 651–659.
62. EFSA Scientific Colloquium Summary Report. QPS: qualified presumption of safety of microorganisms in food and feed. 2004. Available at: https://efsa.onlinelibrary.wiley.com/doi/epdf/10.2903/sp.efsa.2005.EN-109. Accessed October 29, 2018.
63. Sanders, M.E., Akkermans, L.M., Haller, D., et al. Safety assessment of probiotics for human use. Gut Microbes 1 (2010), 164–185.
64. Gibson, G.R., Beatty, E.R., Wang, X., Cummings, J.H., Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin. Gastroenterology 108 (1995), 975–982.
65. Hidaka, H., Hirayama, M., Tokunaga, T., Eida, T., The effects of undigestible fructooligosaccharides on intestinal microflora and various physiological functions on human health. Adv Exp Med Biol 270 (1990), 105–117.
66. Burokas, A., Arboleya, S., Moloney, R.D., et al. Targeting the microbiota-gut-brain axis: prebiotics have anxiolytic and antidepressant-like effects and reverse the impact of chronic stress in mice. Biol Psychiatry 82 (2017), 472–487.
67. Petrof, E.O., Kojima, K., Ropeleski, M.J., et al. Probiotics inhibit nuclear factor-kappaB and induce heat shock proteins in colonic epithelial cells through proteasome inhibition. Gastroenterology 127 (2004), 1474–1487.
68. Di Marzio, L., Russo, F.P., D'Alo, S., et al. Apoptotic effects of selected strains of lactic acid bacteria on a human T leukemia cell line are associated with bacterial arginine deiminase and/or sphingomyelinase activities. Nutr Cancer 40 (2001), 185–196.
69. Maassen, C.B., van Holten-Neelen, C., Balk, F., et al. Strain-dependent induction of cytokine profiles in the gut by orally administered Lactobacillus strains. Vaccine 18 (2000), 2613–2623.
70. Morita, H., He, F., Fuse, T., et al. Adhesion of lactic acid bacteria to caco-2 cells and their effect on cytokine secretion. Microbiol Immunol 46 (2002), 293–297.
71. Ma, D., Forsythe, P., Bienenstock, J., Live Lactobacillus reuteri is essential for the inhibitory effect on tumor necrosis factor alpha-induced interleukin-8 expression. Infect Immun 72 (2004), 5308–5314.
72. West, C.E., Jenmalm, M.C., Prescott, S.L., The gut microbiota and its role in the development of allergic disease: a wider perspective. Clin Exp Allergy 45 (2015), 43–53.
73. Konieczna, P., Akdis, C.A., Quigley, E.M., et al. Portrait of an immunoregulatory Bifidobacterium. Gut Microbes 3 (2012), 261–266.
74. Cao, Y., Shen, J., Ran, Z.H., Association between Faecalibacterium prausnitzii reduction and inflammatory bowel disease: a meta-analysis and systematic review of the literature. Gastroenterol Res Pract, 2014, 2014, 872725.
75. Rossi, O., van Berkel, L.A., Chain, F., et al. Faecalibacterium prausnitzii A2-165 has a high capacity to induce IL-10 in human and murine dendritic cells and modulates T cell responses. Sci Rep, 6, 2016, 18507.
76. Martín, R., Miquel, S., Chain, F., et al. Faecalibacterium prausnitzii prevents physiological damages in a chronic low-grade inflammation murine model. BMC Microbiol, 15, 2015, 67.
77. Shiba, T., Aiba, Y., Ishikawa, H., et al. The suppressive effect of bifidobacteria on Bacteroides vulgatus, a putative pathogenic microbe in inflammatory bowel disease. Microbiol Immunol 47 (2003), 371–378.
78. Servin, A.L., Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens. FEMS Microbiol Rev 28 (2004), 405–440.
79. Sartor, R.B., Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 126 (2004), 1620–1633.
80. Constante, M., Fragoso, G., Lupien-Meilleur, J., Calvé A., Santos, M.M., Iron supplements modulate colon microbiota composition and potentiate the protective effects of probiotics in dextran sodium sulfate-induced colitis. Inflamm Bowel Dis 23 (2017), 753–766.
81. Victor, D.W. 3rd, Quigley, E.M., The microbiome and the liver: the basics. Semin Liver Dis 36 (2016), 299–305.
82. Picard, C., Fioramonti, J., Francois, A., Robinson, T., Neant, F., Matuchansky, C., Review article: bifidobacteria as probiotic agents—physiological effects and clinical benefits. Aliment Pharmacol Ther 22 (2005), 495–512.
83. Lomasney, K.W., Cryan, J.F., Hyland, N.P., Converging effects of a Bifidobacterium and Lactobacillus probiotic strain on mouse intestinal physiology. Am J Physiol Gastrointest Liver Physiol 307 (2014), G241–G247.
84. Srutkova, D., Schwarzer, M., Hudcovic, T., et al. Bifidobacterium longum CCM 7952 promotes epithelial barrier function and prevents acute dss-induced colitis in strictly strain-specific manner. PLoS One, 10, 2015, e0134050.
85. Yan, F., Polk, D.B., Probiotic bacterium prevents cytokine-induced apoptosis in intestinal epithelial cells. J Biol Chem 277 (2002), 50959–50965.
86. Ahrne, S., Hagslatt, M.L., Effect of lactobacilli on paracellular permeability in the gut. Nutrients 3 (2011), 104–117.
87. Lomasney, K.W., Houston, A., Shanahan, F., et al. Selective influence of host microbiota on cAMP-mediated ion transport in mouse colon. Neurogastroenterol Motil 26 (2014), 887–890.
88. Souza, É.L., Elian, S.D., Paula, L.M., et al. Escherichia coli strain Nissle 1917 ameliorates experimental colitis by modulating intestinal permeability, the inflammatory response and clinical signs in a faecal transplantation model. J Med Microbiol 65 (2016), 201–210.
89. Mack, D.R., Ahrne, S., Hyde, L., Wei, S., Hollingsworth, M.A., Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro. Gut 52 (2003), 827–833.
90. Verdu, E.F., Bercik, P., Verma-Gandhu, M., et al. Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice. Gut 55 (2006), 182–190.
91. Ait-Belgnaoui, A., Han, W., Lamine, F., et al. Lactobacillus farciminis treatment suppresses stress-induced visceral hypersensitivity: a possible action through interaction with epithelial cells cytoskeleton contraction. Gut 55 (2006), 1090–1094.
92. Eutamene, H., Lamine, F., Chabo, C., et al. Synergy between Lactobacillus paracasei and its bacterial products to counteract stress-induced gut permeability and sensitivity increase in rats. J Nutr 137 (2007), 1901–1907.
93. McKernan, D.P., Fitzgerald, P., Dinan, T.G., et al. The probiotic Bifidobacterium infantis 35624 displays visceral antinociceptive effects in the rat. Neurogastroenterol Motil 22 (2010), 1029–1035.
94. Johnson, A.C., Greenwood-Van Meerveld, B., McRorie, J., Effects of Bifidobacterium infantis 35624 on post-inflammatory visceral hypersensitivity in the rat. Dig Dis Sci 56 (2011), 3179–3186.
95. Agrawal, A., Houghton, L.A., Morris, J., et al. Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173-010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Aliment Pharmacol Ther 29 (2009), 104–114.
96. Verdu, E.F., Bercik, P., Bergonzelli, G.E., et al. Lactobacillus paracasei normalizes muscle hypercontractility in a murine model of postinfective gut dysfunction. Gastroenterology 127 (2004 Sep), 826–837.
97. Desbonnet, L., Garrett, L., Clarke, G., et al. Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression. Neuroscience 170 (2010), 1179–1188.
98. Bercik, P., Denou, E., Collins, J., et al. The intestinal microbiota affect central levels of brain-derived neurotrophic factor and behavior in mice. Gastroenterology 141 (2011), 599–609.
99. Bravo, J.A., Forsythe, P., Chew, M.V., et al. Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc Natl Acad Sci U S A 108 (2011), 16050–16055.
100. Desbonnet, L., Clarke, G., Shanahan, F., Dinan, T.G., Cryan, J.F., Microbiota is essential for social development in the mouse. Mol Psychiatry 19 (2014), 146–148.
101. Emge, J.R., Huynh, K., Miller, E.N., et al. Modulation of the microbiota-gut-brain axis by probiotics in a murine model of inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 310 (2016), G989–G998.
102. Charbonneau, D., Gibb, R.D., Quigley, E.M., Fecal excretion of Bifidobacterium infantis 35624 and changes in fecal microbiota after eight weeks of oral supplementation with encapsulated probiotic. Gut Microbes 4 (2013), 201–211.
103. Kolmeder, C.A., Salojarvi, J., Ritari, J., et al. Faecal metaproteomic analysis reveals as personalized and stable functional microbiome and limited effects of a probiotic intervention in adults. PLoS One, 11, 2016, e0153294.
104. Konieczna, P., Groeger, D., Ziegler, M., et al. Bifidobacterium infantis 35624 administration induces Foxp3 T regulatory cells in human peripheral blood: potential role for myeloid and plasmacytoid dendritic cells. Gut 61 (2012), 354–366.
105. Groeger, D., O'Mahony, L., Murphy, E.F., et al. Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut. Gut Microbes 4 (2013), 325–339.
106. Pinto-Sanchez, M.I., Hall, G.B., Ghajar, K., et al. Probiotic Bifidobacterium longum NCC3001 reduces depression scores and alters brain activity: a pilot study in patients with irritable bowel syndrome. Gastroenterology 153 (2017), 448–459.
107. Panpetch, W., Spinler, J.K., Versalovic, J., Tumwasorn, S., Characterization of Lactobacillus salivarius strains B37 and B60 capable of inhibiting IL-8 production in Helicobacter pylori-stimulated gastric epithelial cells. BMC Microbiol, 16, 2016, 242.
108. Zeber-Lubecka, N., Kulecka, M., Ambrozkiewicz, F., et al. Limited prolonged effects of rifaximin treatment on irritable bowel syndrome-related differences in the fecal microbiome and metabolome. Gut Microbes 7 (2016), 397–413.
109. Mazurak, N., Broelz, E., Storr, M., Enck, P., Probiotic therapy of the irritable bowel syndrome: why is the evidence still poor and what can be done about it?. J Neurogastroenterol Motil 21 (2015), 471–485.
110. Abraham, B.P., Quigley, E.M.M., A probiotic for ulcerative colitis: the culture wars continue. Dig Dis Sci 63 (2018), 1678–1680.
111. Ford, A.C., Quigley, E.M., Lacy, B.E., et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol 109 (2014), 1547–1561.
112. Khalesi, S., Bellissimo, N., Vandelanotte, C., Williams, S., Stanley, D., Irwin, C., A review of probiotic supplementation in healthy adults: helpful or hype?. Eur J Clin Nutr, 2018 Mar 26 [E-pub ahead of print].
113. Kellow, N.J., Coughlan, M.T., Reid, C.M., Metabolic benefits of dietary prebiotics in human subjects: a systematic review of randomised controlled trials. Br J Nutr 111 (2014), 1147–1161.
114. Dewulf, E.M., Cani, P.D., Claus, S.P., et al. Insight into the prebiotic concept: lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women. Gut 62 (2013), 1112–1121.
115. Guarner F, Sanders ME, Eliakim R, et al. Probiotics and prebiotics. World Gastroenterology Organisation Global Guidelines. 2017. Available at: http://www.worldgastroenterology.org/UserFiles/file/guidelines/probiotics-and-prebiotics-english-2017.pdf. Accessed October 29, 2018.
116. OCEBM levels of evidence. Available at: http://www.cebm.net/index.aspx?o=5653, 2016 Accessed October 29, 2018.
117. Panigrahi, P., Parida, S., Nanda, N.C., et al. A randomized synbiotic trial to prevent sepsis among infants in rural India. Nature 548 (2017), 407–412.
118. Goldenberg, J.Z., Lytvyn, L., Steurich, J., Parkin, P., Mahant, S., Johnston, B.C., Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev, 12, 2015, CD004827.
119. Goldenberg, J.Z., Yap, C., Lytvyn, L., et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev, 12, 2017, CD006095.
120. Shen, N.T., Maw, A., Tmanova, L.L., et al. Timely use of probiotics in hospitalized adults prevents clostridium difficile infection: a systematic review with meta-regression analysis. Gastroenterology 152 (2017), 1889–1900.
121. Johnston, B.C., Lytvyn, L., Lo, C.K., et al. Microbial preparations (probiotics) for the prevention of clostridium difficile infection in adults and children: an individual patient data meta-analysis of 6,851 participants. Infect Control Hosp Epidemiol 39 (2018), 771–781.
122. Liu, M.M., Li, S.T., Shu, Y., Zhan, H.Q., Probiotics for prevention of radiation-induced diarrhea: A meta-analysis of randomized controlled trials. PLoS One, 12, 2017, e0178870.
123. Lawrie, T.A., Green, J.T., Beresford, M., et al. Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic cancers. Cochrane Database Syst Rev, 1, 2018, CD012529.
124. Derwa, Y., Gracie, D.J., Hamlin, P.J., Ford, A.C., Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease. Aliment Pharmacol Ther 46 (2017), 389–400.
125. Bernaola Aponte, G., Bada Mancilla, C.A., Carreazo, N.Y., Rojas Galarza, R.A., Probiotics for treating persistent diarrhoea in children. Cochrane Database Syst Rev, 8, 2013, CD007401.
126. Freedman, S.B., Pasichnyk, D., Black, K.J., et al. Pediatric Emergency Research Canada Gastroenteritis Study Group. Gastroenteritis therapies in developed countries: systematic review and meta-analysis. PLoS One, 10, 2015, e0128754.
127. Urbańska, M., Gieruszczak-Białek, D., Szajewska, H., Systematic review with meta-analysis: Lactobacillus reuteri DSM 17938 for diarrhoeal diseases in children. Aliment Pharmacol Ther 43 (2016), 1025–1034.
128. Lu, C., Sang, J., He, H., et al. Probiotic supplementation does not improve eradication rate of Helicobacter pylori infection compared to placebo based on standard therapy: a meta-analysis. Sci Rep, 6, 2016, 23522.
129. Lü M., Yu, S., Deng, J., et al. Efficacy of probiotic supplementation therapy for Helicobacter pylori eradication: a meta-analysis of randomized controlled trials. PLoS One, 11, 2016, e0163743.
130. Malfertheiner, P., Megraud, F., O'Morain, C.A., et al. European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 66 (2017), 6–30.
131. Dalal, R., McGee, R.G., Riordan, S.M., Webster, A.C., Probiotics for people with hepatic encephalopathy. Cochrane Database Syst Rev, 2, 2017, CD008716.
132. Ford, A.C., Moayyedi, P., Chey, W.D., et al. ACG Task Force on Management of Irritable Bowel Syndrome. American College of Gastroenterology monograph on management of irritable bowel syndrome. Am J Gastroenterol 113:Suppl 2 (2018), 1–18.
133. Singh, S., Stroud, A.M., Holubar, S.D., Sandborn, W.J., Pardi, D.S., Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev, 2015, CD001176.
134. Newlove-Delgado, T.V., Martin, A.E., Abbott, R.A., et al. Dietary interventions for recurrent abdominal pain in childhood. Cochrane Database Syst Rev, 3, 2017, CD010972.
135. Pinos, Y., Castro-Gutiérrez, V., Rada, G., Are probiotics effective to prevent traveler's diarrhea?. Medwave, 16, 2016, e6807.
136. Hiippala, K., Jouhten, H., Ronkainen, A., et al. The potential of gut commensals in reinforcing intestinal barrier function and alleviating inflammation. Nutrients, 10, 2018, E988.